Chiome Bioscience Inc. (TYO:4583)
107.00
-2.00 (-1.83%)
At close: Mar 6, 2026
Chiome Bioscience Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,205 | 2,063 | 1,326 | 1,727 | 1,791 |
Cash & Short-Term Investments | 1,205 | 2,063 | 1,326 | 1,727 | 1,791 |
Cash Growth | -41.60% | 55.65% | -23.26% | -3.56% | -33.33% |
Accounts Receivable | 72 | 51.06 | 83.19 | 115.22 | 25.46 |
Other Receivables | 29.52 | 24.43 | 25.05 | 29.57 | 36.05 |
Receivables | 101.52 | 75.49 | 108.24 | 144.79 | 61.51 |
Inventory | 49.41 | 46.17 | 64.11 | 71.48 | 59.05 |
Prepaid Expenses | 55.04 | 46.66 | 43.85 | 57.15 | 34.47 |
Other Current Assets | 135.71 | 106.08 | 87.65 | 91.48 | 270.87 |
Total Current Assets | 1,547 | 2,338 | 1,629 | 2,092 | 2,217 |
Property, Plant & Equipment | 36.34 | - | 1.17 | 2.44 | 4.2 |
Other Long-Term Assets | 144.47 | 131.19 | 120.89 | 120.87 | 118.36 |
Total Assets | 1,728 | 2,469 | 1,751 | 2,215 | 2,339 |
Accounts Payable | 37.44 | 27.2 | 37.74 | 31.87 | 29.81 |
Accrued Expenses | 14.56 | 29.56 | 32.32 | 32.91 | 44.46 |
Short-Term Debt | 86.7 | 281.5 | 291 | 184 | 183 |
Current Income Taxes Payable | 12.55 | 2.53 | 23.95 | 23.94 | 16.75 |
Current Unearned Revenue | 130.33 | - | - | - | - |
Other Current Liabilities | 93.31 | 152.65 | 154.03 | 97.74 | 118.53 |
Total Current Liabilities | 374.89 | 493.43 | 539.04 | 370.46 | 392.54 |
Other Long-Term Liabilities | 230.56 | 55.12 | 54.69 | 54.27 | 53.85 |
Total Liabilities | 605.44 | 548.55 | 593.73 | 424.72 | 446.39 |
Common Stock | 1,086 | 995.53 | 2,388 | 2,097 | 1,516 |
Retained Earnings | 22.24 | 915.02 | -1,248 | -319.53 | 342.02 |
Treasury Stock | -0.29 | -0.29 | -0.29 | -0.29 | -0.29 |
Comprehensive Income & Other | 14.59 | 10.05 | 17.74 | 13.55 | 35.4 |
Total Common Equity | 1,122 | 1,920 | 1,158 | 1,791 | 1,893 |
Shareholders' Equity | 1,122 | 1,920 | 1,158 | 1,791 | 1,893 |
Total Liabilities & Equity | 1,728 | 2,469 | 1,751 | 2,215 | 2,339 |
Total Debt | 86.7 | 281.5 | 291 | 184 | 183 |
Net Cash (Debt) | 1,118 | 1,782 | 1,035 | 1,543 | 1,608 |
Net Cash Growth | -37.23% | 72.23% | -32.96% | -4.03% | -35.84% |
Net Cash Per Share | 16.47 | 30.61 | 20.88 | 35.09 | 39.92 |
Filing Date Shares Outstanding | 68.44 | 66.96 | 52.63 | 48.42 | 40.78 |
Total Common Shares Outstanding | 68.44 | 66.96 | 52.63 | 48.42 | 40.78 |
Working Capital | 1,172 | 1,844 | 1,090 | 1,722 | 1,824 |
Book Value Per Share | 16.39 | 28.68 | 22.00 | 36.98 | 46.42 |
Tangible Book Value | 1,122 | 1,920 | 1,158 | 1,791 | 1,893 |
Tangible Book Value Per Share | 16.39 | 28.68 | 22.00 | 36.98 | 46.42 |
Machinery | 329.98 | 312.86 | 318.96 | 351.63 | 387.39 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.